Protocol BT-23, a Phase II study, was performed to determine the efficacy and safety of combination Antineoplaston A10 and Antineoplaston AS2-1 (ANP) in children with an optic pathway glioma (OPG). Sixteen patients (12 males, 4 females) ages 1 to 16 years (median age 4.5 years) were treated. The patients received ANP, by intravenous infusion, six times daily (i.e., every four hours). The length of treatment extended from a minimum of 4.1 weeks to a maximum of 210.0 weeks. The median dosage of A10 was 8.07 g/kg/d while for AS2-1 it was 0.39 g/kg/d.
Introduction
Optic pathway gliomas (OPG) constitute approximately 6% of pediatric brain tumors (Jahraus & Tarbell, 2006; Thiagalingam, Flaherty, Billson & North, 2004) . Typically occurring in children younger than 12 years of age, they primarily involve the optic chiasm and the hypothalamus, but can involve the optic nerve (Edwards & Cogen, 1994; Janss et al., 1995) . Treatment is individualized and prognosis varies. Chiasmatic and hypothalamic tumors are more likely to result in loss of vision and hypothalamic dysfunction, than are gliomas of the optic nerve. However, intra-orbital tumors can also cause loss of vision, as well as proptosis and strabismus. Optic pathway gliomas are the most common type of brain tumor associated with neurofibromatosis 1 (NF-1) and growth of the glioma in some NF-1 patients is so slow that treatment is usually not recommended (Pollack & Mulvihill, 1996; Tow, Chandela, Miller & Avellino, 2003) . OPGs that occur before the age of one year frequently show a more aggressive growth pattern (Opocher, Kremer, Da Dalt, van de Wetering, Viscardi, Caron & Perilongo, 2006) . Children and adolescents with OPG are generally not candidates for curative surgery. However, when the tumor has a prominent exophytic component, a subtotal resection can be accomplished (Wisoff, Abbott & Epstein, 1990) . Following such a resection, progression-free intervals of greater than 2 years have been reported (Wisoff et al., 1990) .
Due to concerns relating to acute and delayed toxicity after radiation therapy, a number of chemotherapeutic regimens have been used in the treatment of OPGs in children and adolescents (Burzynski, 2006) . While complete responses (CR) to chemotherapy are unusual, partial response (PR) rates can be substantial (Laithier et al., 2003) . Such responses can delay the need for RT (Laithier et al., 2003; Gururangan et al., 2002; Gnekow, Kortmann, Pietsch & Emser, 2004; Gururangan, et al., 2007) . The most widely used chemotherapeutic regimen for the treatment of progressive, low-grade gliomas in children and adolescents is a combination of carboplatin and vincristine (Gururangan et al., 2002; Gnekow et al., 2004) . Multiagent platinum-based regimens and nitrosourea-based regimens are also employed (Opocher et al., 2006; Laithier et al., 2003) . Temozolomide (TMZ) is reported to be successful in stabilizing disease in 50% of pediatric patients treated (PR in 12% and stable disease (SD) in 38%) (Gururangan et al., 2002) . However, the long-term results with TMZ are not as favorable as those obtained using carboplatin containing regimens. There is no doubt that chemotherapy has been successful in stabilizing the disease. Unfortunately, chemotherapy has not cured the disease nor provided a high quality of life for the great majority of patients. Chronic toxicity continues to be a major problem (Burzynski, 2006) . Antineoplastons A10 and AS2-1 are synthetic derivatives of glutamine, isoglutamine, and phenylacetic acid (Burzynski, 2004) . A10 is a synthetic formulation consisting of a 4:1 ratio of phenylacetylglutaminate sodium (PG) and phenylacetylisoglutaminate sodium (isoPG). AS2-1 is a synthetic formulation with a 4:1 ratio of phenylacetate sodium (PN) and PG.
In a Phase II study of ANP in patients with an astrocytoma, which was opened for enrollment in 1988, a CR with more than 28 years of progression-free survival (PFS) was documented in a 7-year-old child diagnosed with a large, inoperable OPG (S Burzynski, Kubove & B Burzynski, 1992; Hawkins & Friedman, 1992) . This patient, who had a short life expectancy and was never treated with RT or chemotherapy, is tumor-free and continues to enjoy good health and a productive life. Additional Phase II studies utilizing ANP have shown objective responses (OR) and improved survival in pediatric high-grade glioma, diffuse intrinsic pontine glioma (DIPG) and low-grade astrocytoma (S Burzynski, Janicki, G , 2051 -2061 S Burzynski, Janicki, G Burzynski & Marszalek, 2015, 334-344; S Burzynski, Janicki, G Burzynski & Marszalek, 2014, 565-577; S Burzynski, Janicki, G Burzynski, Marszalek & Brookman, 2014, 977-988; , e433-e439, S Burzynski, Janicki, G Burzynski, 2016 . Such encouraging preliminary data prompted this single-arm Phase II study of ANP in children with an OPG.
Materials and Methods

Patient Population
This Phase II study accrued patients less than 18 years of age, but more than 6 months of age, who had radiologic evidence of OPG by gadolinium-enhanced magnetic resonance imaging (MRI), which is the diagnostic imaging study of choice (Gutmann & MacCollin, 2001) , performed within 14 days of the start of ANP. The diagnosis of OPG generally does not require a biopsy.
Study Design
Except of diagnosis specific to the protocol, the inclusion and exclusion criteria, as well as reasons for removal from the study, have previously been described (S Burzynski, Janicki, G Burzynski & Marszalek, 2014, 565-577) . Additional patients, including those with a Lansky or Karnofsky score ≤ 50, were enrolled on a case-by-case basis with an exception granted by the FDA. All patients and/or guardians signed an Informed Consent Document prior to enrollment. This Phase II study was a single-arm, two-stage, interventional trial of ANP in a high-risk, poor-prognosis study population (Chang et al., 1999) . It commenced on June 27, 1996 under IND 43,742 and after approval by the BRI-IRB. The last patient began ANP on 10/13/2004.
The study protocol was amended on occasion, but none of the amendments altered the aim or design of the original study objectives/outcomes or introduced new safety issues.
Statistical Considerations
This was a two-stage study with 20 patients being enrolled in the first stage. If one OR occurred among these patients, up to 20 additional patients could be enrolled (Chang et al., 1999) . At the completion of the study, an overall OR rate of ≥ 10% (i.e., 4 ORs) was considered to warrant further study.
Administration of the Medications
The details of ANP administration have been previously published (Burzynski et al., , 2051 (Burzynski et al., -2061 Burzynski et al., 2015; Burzynski et al., 2014, 565-577; Burzynski et al., 2014, 977-988) . Escalation of the dosage of ANP is based on the results of prior studies carried out to determine patients' tolerance of the infusion of the large volume of intravenous fluids necessary to deliver the higher doses of ANP (Burzynski, 2004) . As a safety precaution, escalation of the dosage of ANP will continue through Phase II and Phase III trials.
Medications that were considered necessary for the subjects' welfare and that did not interfere with the evaluation of treatment were given at the discretion of the investigator. The use of corticosteroids was carefully monitored and the smallest dosages compatible with preservation of optimal neurologic functions were utilized.
Treatment with other antineoplastic or immunomodulatory agents was not permitted during the study. Subjects received full supportive care, including transfusions of blood products and antibiotics when appropriate.
Evaluation and Follow-up
OR rates for target lesions were determined using the RANO criteria (Response Assessment in Neuro-Oncology) as assessed by an MRI with gadolinium enhancement. A CR was achieved when disappearance of all disease was sustained for at least four weeks. A PR was achieved with a ≥ 50% decrease in the sum of the products of the greatest perpendicular diameters of all target lesions, compared to baseline, and sustained for at least four weeks. SD was maintained by a < 50% decrease in the sum of the products of the greatest perpendicular diameters of all target lesions, compared to baseline, and no progressive disease (PD), sustained for at least four weeks. PD was determined by a ≥ 25% increase in the sum of the products of the greatest perpendicular diameters of all target lesions compared to the lowest sum previously recorded. Target lesions were contrast-enhancing lesions ≥ 5 mm in size. (Wen et al., 2010; Weller, Cloughesy, Perry & Wick, 2013) .
Details of the evaluation of overall survival (OS) and adverse drug experiences (ADEs) have been previously described (S Burzynski, Janicki, G Burzynski, 2016, 837-850) .
Results
Patient Demographics
Subject enrollment started June 27, 1996, and continued through October 13, 2004. As of June 5, 2008, all subjects had permanently discontinued ANP due to the achievement of a CR, subject request, PD, or a worsening clinical condition. The 16 patients enrolled had a median age of 4.5 years while. 25% were female and 75% were male. All patients were Caucasian.
Patient characteristics are shown in Table 1 . Note. CH-chemotherapy, L-leptomeningeal involvement, MC-multicentric, MF-multifocal, NF-1-neurofibromatosis 1, OPG-optic pathway glioma, RT-radiation therapy, SU -surgery, W-white
Treatment
The trial enrolled 16 study subjects. Three patients received special consideration (one had a Lansky/Karnofsky score of 40 and two had scores of 50). One patient was enrolled despite a lack of tumor contrast enhancement at baseline. Of the 16 patients enrolled, 2 (12.5%) achieved a CR, 3 achieved a PR (18.8%), 5 (31.3%) maintained SD, while 2 (12.5%) developed PD; the remaining 4 patients did not have follow-up MRIs to be classified. ORs were achieved following a median of 57 weeks of ANP (range, 6 to 177 weeks). The duration of SD ranged from 5.9 to 179.4 months. Characteristics of the patients who achieved a CR or PR are shown in Table 2 . 
Response and Survival
It has been suggested that Phase II studies should also determine survival data (Iwamoto & Lassman, 2015) . Therefore, this report includes a survival analysis.
The OS and PFS data for patients living at the time of last contact are presented in Table 4 presents a comparison of our study with other studies reported in the current literature, which utilized chemotherapeutic agents in the treatment of OPG. Note. CR-complete response, PR-partial response, SD-stable disease, yrs-year Survival analysis revealed a median PFS of 45.4 months and a PFS at 6 months of 75.0%.
The OS at 2 years was 81%, at 4 years it was 67%, at 5 years it was 67%, and at 10 and 15 years it was 37%. The median OS was 78.5 months. The Kaplan-Meier survival curve is shown in Figure 2 . 
Safety and Adverse Drug Events
All 16 patients were included in the analysis of toxicity. Patients were initially treated at the Burzynski Clinic. Two or more weeks later, when the patient and/or guardian had been adequately educated in the administration of ANP, they went home. Both at the Burzynski Clinic and at home (via telephone), patients were questioned on a daily basis concerning possible ADEs. After two months, questioning was conducted on a weekly basis. Adverse events were categorized according to CTCAE v 3.0. Table 5 compares the incidence of grade 3 and 4 ADEs in our study to that reported by others. No long-term ADEs to ANP were reported. 
Discussion
The successful treatment of OPG, which is not amenable to complete resection, continues to present a clinical challenge. Most of these tumors arise in children younger than five years of age, and their behavior is unpredictable, ranging from spontaneous regression in some patients with neurofibromatosis I to continued neurological impairment leading to disability and death. Most of the reported studies combine patients diagnosed with OPG with low-grade glioma (LGG), and only a small number of clinical investigations deal with OPG exclusively. The studies on LGG have been extensively reviewed in medical literature (Tow et al., 2003; Opocher et al., 2006; Wisoff et al., 1990; Burzynski, 2006; Laithier et al., 2003) . Large scale studies have been performed by various groups to develop a comprehensive treatment strategy for all patients with OPG (Laithier et al., 2003; Gnekow et al., 2004) . These studies emphasize chemotherapy, but the patients were also treated surgically and with radiation therapy (RT). The main goal was to defer RT by introducing initial combination chemotherapy.
In the study organized by the French Society of Pediatric Oncology, 85 patients were treated with alternating cycles of procarbazine and carboplatin, etoposide and cisplatin, and vincristine and cyclophosphamide, and were followed with RT at progression (Laithier et al., 2003) . There were no CRs, but 42% of patients accomplished PR and 45% SD. Unfortunately, most of these patients developed disease progression, indicated by PFS of 34% at five years.
The German Society of Pediatric Oncology and Hematology (GPOH) reported the results of the treatment of 123 patients with vincristine and carboplatin followed by RT at progression (Gnekow et al., 2004) . The response rate was CR 2%, PR 6%, and 76% SD. Inevitably, there was progression of the disease, but PFS at five years was reported as 60%.
There are only a small number of reports on Phase II studies in OPG with single chemotherapy regimens and without added RT. The results of two of these studies, utilizing carboplatin and temozolomide, respectively, along with the results of our study, are presented in Table 4 . These three studies enrolled a similar number of patients, but there was a markedly higher CR rate (12.5%) in our study compared to a 2% rate in the carboplatin study and no CRs reported in the temozolomide study (Gururangan, et al., 2002; Gururangan, et al., 2007) . There were no PRs reported in the temozolomide study while carboplatin treatment provided for a 21% PR rate. There was an 18.8% PR rate in patients utilizing ANP. SD was in the 50% range for chemotherapy studies and was 31.3% in patients utilizing ANP.
The carboplatin study did not present survival data beyond two years, but overall survival in the temozolomide trial was 57% at three years and 7% at five years, which is comparable to 62% at three years and 56% at five years for ANP. OS in excess of 10 and 15 years with ANP (44%) is substantial. Most patients treated in this study at the Burzynski Clinic had developed tumor recurrence after prior treatments. Fifty percent underwent prior surgical resection and 31% relapsed after combination chemotherapy before coming to BC. While less disabling than RT, long-term toxicity compromises the survival of children with OPG who are treated with chemotherapy (Burzynski, 2006) . Chronic myelosuppression (Perilongo, 2005; De Vita, Carbone, Owens, Gold, Krant & Edmonson, 1965; Kumar & Dua, 1987; Calvert, Newell & Gore, 1992) , gonadal dysfunction (Calvert et al., 1992; Rivkees & Crawford, 1988; Roth, Einhorn & Greist, 1988; Clayton, Shalet, Price & Jones, 1989) , renal insufficiency (Schilsky, Sherins, Hubbard, Wesley, Young & DeVita, 1981; Goren, Wright & Horowitz, 1986; Schacht & Baldwin, 1978) , pulmonary toxicity (Goren et al., 1986; Schacht et al., 1978; Holoye, Jenkins & Greenberg, 1976; Jones, Moore, Blank & Castellino, 1972) , neurotoxicity (Jones et al., 1972; Shingleton, Bienfang, Albert, Ensminger, Chandler & Greenberg, 1982; Weiss, Walker & Wiernik, 1974; Grunberg, Sonka, Stevenson & Muggia, 1989) including hearing loss (Grunberg et al., 1989; Hansen, Helwig-Larsen & Trojaborg, 1989; Schaefer, Post, Close & Wright, 1985) can develop. The use of carmustine and lomustine in the treatment of patients with gliomas is associated with myelofibrosis, secondary myelodysplasia and acute leukemia (Greene, Boice & Strike, 1985; Cohen, Wiernik & Walker, 1976) .
As indicated by Table 5 , treatment with carboplatin and temozolomide is generally less toxic than treatment with carmustine and lomustine, but is associated with a high percentage of Grade 3 and 4 thrombocytopenia and neutropenia. In addition, approximately 17% of patients in the carboplatin study developed serious infection.
ANP is much better tolerated than cytotoxic chemotherapy. With ANP, there was only a small number of easily reversible Grades 3 and 4 toxicities. There were no chronic ADEs in the ANP study and the quality of survival was very high. A significant number of patients whose tumors went into remission experienced survival in excess of 15 years, with a high quality of life. It is recognized that any single-arm Phase II study is limited by the lack of a control population. However, the patient population in this study was representative of the general population at risk. Efficacy and safety were properly evaluated. Future studies with a larger population of patients can evaluate the efficacy of this regimen in greater detail. It is recognized that OPG comprises a heterogeneous group of brain tumors with over 800 genomic and numerous epigenomic abnormalities (Marko & Weil, 2012) . Currently our group is striving to identify these abnormalities in our patient population and to correlate them with response to ANP.
Conclusion
This small Phase II study demonstrated an objective response rate of 31.3% and an overall disease stabilization rate of 62.5%. The long-term survival characteristics are attractive, with 66% OS at five years and 37% OS at 15 years. The safety and efficacy of ANP is remarkable with no chronic toxicities and only a small number of easily reversible Grades 3 and 4 toxicities. In future studies it will be important to determine the -genomic signature‖ of response to ANP. Based on this study, there is now evidence-based research supporting the safety and efficacy of ANP in the treatment of OPG, which should be confirmed by further studies.
